Business News • PR NewsWire • Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

TARRYTOWN, N.Y. and PARIS, March 11, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA®) in...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-topline-results-of-phase-3-monotherapy-study-demon...

Releted News by prnewswire

Pet Products Market (Pet Care, Food) Top Trends Studied in New 2016 Research Report

U.S. Census Bureau Daily Feature for March 11: Deadly Influenza